

# Laura Senovilla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/903127/publications.pdf>

Version: 2024-02-01

80  
papers

8,568  
citations

61687

45  
h-index

75989

78  
g-index

81  
all docs

81  
docs citations

81  
times ranked

16179  
citing authors

#	ARTICLE	IF	CITATIONS
1	In Vivo Imaging of Orthotopic Lung Cancer Models in Mice. <i>Methods in Molecular Biology</i> , 2021, 2279, 199-212.	0.4	5
2	Clonogenic Assays to Detect Cell Fate in Mitotic Catastrophe. <i>Methods in Molecular Biology</i> , 2021, 2267, 227-239.	0.4	3
3	Quantification of eIF2 $\pm$ Phosphorylation Associated with Mitotic Catastrophe by Immunofluorescence Microscopy. <i>Methods in Molecular Biology</i> , 2021, 2267, 217-226.	0.4	2
4	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. <i>Cell Death and Disease</i> , 2021, 12, 978.	2.7	9
5	Paradoxical implication of BAX/BAK in the persistence of tetraploid cells. <i>Cell Death and Disease</i> , 2021, 12, 1039.	2.7	7
6	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
7	Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. <i>Oncolmmunology</i> , 2019, 8, e1656502.	2.1	45
8	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. <i>Oncolmmunology</i> , 2019, 8, 1657374.	2.1	36
9	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
10	eIF2 $\pm$ phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018, 25, 1375-1393.	5.0	162
11	Calcium signaling and cell cycle: Progression or death. <i>Cell Calcium</i> , 2018, 70, 3-15.	1.1	152
12	Immune effectors responsible for the elimination of hyperploid cancer cells. <i>Oncolmmunology</i> , 2018, 7, e1463947.	2.1	14
13	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
14	Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. <i>Methods in Molecular Biology</i> , 2017, 1524, 53-64.	0.4	8
15	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
16	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Oncolmmunology</i> , 2016, 5, e1160193.	2.1	11
17	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. <i>Oncolmmunology</i> , 2016, 5, e1174801.	2.1	10
18	The ratio of CD8 <sup>+</sup> /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmmunology</i> , 2016, 5, e1218106.	2.1	50

#	ARTICLE	IF	CITATIONS
19	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1139275.	2.1	21
20	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
21	eIF2 $\gamma$ phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , 2015, 33, 86-92.	4.3	95
22	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. <i>Trends in Cancer</i> , 2015, 1, 124-135.	3.8	28
23	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015, 21, 1128-1138.	15.2	268
24	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
25	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015, 6, 41204-41215.	0.8	13
26	Chemosensitization strategies for the treatment of lung cancer. <i>Oncoscience</i> , 2015, 2, 833-834.	0.9	0
27	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
28	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
29	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Oncolmmunology</i> , 2014, 3, e28473.	2.1	112
30	Coffee induces autophagy in vivo. <i>Cell Cycle</i> , 2014, 13, 1987-1994.	1.3	49
31	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>Oncolmmunology</i> , 2014, 3, e955685.	2.1	16
32	Regulation of Autophagy by Cytosolic Acetyl-Coenzyme A. <i>Molecular Cell</i> , 2014, 53, 710-725.	4.5	412
33	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3020-3025.	3.3	59
34	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , 2014, 30, 24-31.	2.4	35
35	Immunogenic cell death inducers as anticancer agents. <i>Oncotarget</i> , 2014, 5, 5190-5191.	0.8	67
36	Immunosurveillance as a regulator of tissue homeostasis. <i>Trends in Immunology</i> , 2013, 34, 471-481.	2.9	50

#	ARTICLE	IF	CITATIONS
37	Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 57-61.	1.8	7
38	Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. <i>Autophagy</i> , 2013, 9, 415-417.	4.3	48
39	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. <i>Cell Cycle</i> , 2013, 12, 877-883.	1.3	57
40	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 311-318.	3.2	177
41	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23803.	2.1	92
42	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 647-654.	1.3	16
43	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. <i>Oncolmmunology</i> , 2013, 2, e22409.	2.1	20
44	Cisplatin Resistance Associated with PARP Hyperactivation. <i>Cancer Research</i> , 2013, 73, 2271-2280.	0.4	143
45	Analgesic, Anti-Inflammatory and Anticancer Activities of Extra Virgin Olive Oil. <i>Journal of Lipids</i> , 2013, 1-7.	1.9	32
46	Immunosurveillance against tetraploidization-induced colon tumorigenesis. <i>Cell Cycle</i> , 2013, 12, 473-479.	1.3	36
47	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013, 12, 417-421.	1.3	26
48	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23510.	2.1	153
49	Immunostimulatory activity of lifespan-extending agents. <i>Aging</i> , 2013, 5, 793-801.	1.4	27
50	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012, 11, 3472-3480.	1.3	32
51	Tetraploid cancer cell precursors in ovarian carcinoma. <i>Cell Cycle</i> , 2012, 11, 3157-3158.	1.3	6
52	Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity. <i>Molecular Cell</i> , 2012, 48, 667-680.	4.5	239
53	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 257-269.	2.9	122
54	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 1472.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Preferential killing of p53-deficient cancer cells by reversine. <i>Cell Cycle</i> , 2012, 11, 2149-2158.	1.3	34
56	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	21.5	591
57	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684.	6.0	367
58	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1111-1134.	2.1	152
59	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1323-1343.	2.1	203
60	Selective killing of p53-deficient cancer cells by SP600125. <i>EMBO Molecular Medicine</i> , 2012, 4, 500-514.	3.3	47
61	Autophagic removal of micronuclei. <i>Cell Cycle</i> , 2012, 11, 170-176.	1.3	162
62	Immunosurveillance against cancer-associated hyperploidy. <i>Oncotarget</i> , 2012, 3, 1270-1271.	0.8	10
63	Cytofluorometric Purification of Diploid and Tetraploid Cancer Cells. <i>Methods in Molecular Biology</i> , 2011, 761, 47-63.	0.4	5
64	IKK connects autophagy to major stress pathways. <i>Autophagy</i> , 2010, 6, 189-191.	4.3	46
65	The IKK complex contributes to the induction of autophagy. <i>EMBO Journal</i> , 2010, 29, 619-631.	3.5	274
66	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. <i>EMBO Journal</i> , 2010, 29, 1272-1284.	3.5	155
67	Surface-exposed calreticulin in the interaction between dying cells and phagocytes. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 77-82.	1.8	97
68	miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death. <i>Cancer Research</i> , 2010, 70, 1793-1803.	0.4	262
69	Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway. <i>Clinical Cancer Research</i> , 2010, 16, 3100-3104.	3.2	325
70	Involvement of p38 $\beta$ in the mitotic progression of p53 <sup>-/-</sup> tetraploid cells. <i>Cell Cycle</i> , 2010, 9, 2895-2901.	1.3	8
71	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. <i>Cell Cycle</i> , 2010, 9, 2902-2907.	1.3	5
72	Chemotherapy induces ATP release from tumor cells. <i>Cell Cycle</i> , 2009, 8, 3723-3728.	1.3	233

#	ARTICLE	IF	CITATIONS
73	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. <i>Cell Cycle</i> , 2009, 8, 1030-1035.	1.3	40
74	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. <i>Cell Cycle</i> , 2009, 8, 1380-1385.	1.3	38
75	Viral subversion of immunogenic cell death. <i>Cell Cycle</i> , 2009, 8, 860-869.	1.3	60
76	Immunogenic cell death modalities and their impact on cancer treatment. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 364-375.	2.2	185
77	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. <i>Cell Cycle</i> , 2008, 7, 1956-1961.	1.3	41
78	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. <i>Cancer Research</i> , 2008, 68, 5301-5308.	0.4	101
79	Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. <i>PLoS ONE</i> , 2007, 2, e1337.	1.1	67
80	Cell proliferation depends on mitochondrial Ca <sup>2+</sup> uptake: inhibition by salicylate. <i>Journal of Physiology</i> , 2006, 571, 57-73.	1.3	74